1. Home
  2. GENB vs HRMY Comparison

GENB vs HRMY Comparison

Compare GENB & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$12.38

Market Cap

1.9B

Sector

N/A

ML Signal

N/A

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$34.46

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GENB
HRMY
Founded
2018
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
GENB
HRMY
Price
$12.38
$34.46
Analyst Decision
Strong Buy
Buy
Analyst Count
6
9
Target Price
$23.20
$44.11
AVG Volume (30 Days)
829.3K
709.3K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.97
EPS
N/A
0.55
Revenue
N/A
$868,453,000.00
Revenue This Year
N/A
$19.75
Revenue Next Year
$16.58
$12.88
P/E Ratio
N/A
$64.00
Revenue Growth
N/A
21.51
52 Week Low
$11.00
$25.52
52 Week High
$16.75
$40.87

Technical Indicators

Market Signals
Indicator
GENB
HRMY
Relative Strength Index (RSI) 44.12 62.32
Support Level $11.67 $25.92
Resistance Level $13.76 $34.99
Average True Range (ATR) 1.08 1.10
MACD -0.10 0.39
Stochastic Oscillator 12.78 75.30

Price Performance

Historical Comparison
GENB
HRMY

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: